第 1 到 190 筆結果,共 190 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2024 | Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study | Capdevila, Jaume; Krajewska, Jolanta; Hernando, Jorge; Robinson, Bruce; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Williamson, Denise; Levytskyy, Roman; Oliver, Jennifer; Keam, Bhumsuk; Brose, Marcia S | Thyroid : official journal of the American Thyroid Association | |||
2 | 2024 | Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study | Kelly, William K; Danila, Daniel C; CHIA-CHI LIN ; Lee, Jae-Lyun; Matsubara, Nobuaki; Ward, Patrick J; Armstrong, Andrew J; Pook, David; Kim, Miso; Dorff, Tanya B; Fischer, Stefanie; Lin, Yung-Chang; Horvath, Lisa G; Sumey, Christopher; Yang, Zhao; Jurida, Gabor; Smith, Kristen M; Connarn, Jamie N; Penny, Hweixian L; Stieglmaier, Julia; Appleman, Leonard J | Cancer discovery | 6 | ||
3 | 2024 | Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study | Subbiah, Vivek; Hu, Mimi I; Mansfield, Aaron S; Taylor, Matthew H; Schuler, Martin; Zhu, Viola W; Hadoux, Julien; Curigliano, Giuseppe; Wirth, Lori; Gainor, Justin F; Alonso, Guzman; Adkins, Douglas; Godbert, Yann; Ahn, Myung-Ju; Cassier, Philippe A; Cho, Byoung Chul; CHIA-CHI LIN ; Zalutskaya, Alena; Barata, Teresa; Trask, Peter; Scalori, Astrid; Bordogna, Walter; Heinzmann, Sebastian; Brose, Marcia S | Thyroid : official journal of the American Thyroid Association | 1 | ||
4 | 2024 | A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies | CHIA-CHI LIN ; Garralda, Elena; Schöffski, Patrick; Hong, David S; Siu, Lillian L; Martin, Miguel; Maur, Michela; Hui, Rina; Soo, Ross A; Chiu, Joanne; Zhang, Tian; Ma, Brigette; Kyi, Chrisann; Tan, Daniel Sw; Cassier, Philippe A; Sarantopoulos, John; Weickhardt, Andrew; Carvajal, Richard D; Spratlin, Jennifer; Esaki, Taito; Rolland, Fréderic; Akerley, Wallace; Deschler-Baier, Barbara; Rispoli, Lawrence; Samant, Tanay S; Chowdhury, Niladri Roy; Gusenleitner, Daniel; Kwak, Eunice L; Askoxylakis, Vasileios; De Braud, Filippo | Oncoimmunology | 1 | 0 | |
5 | 2024 | Clinical practice consensus for the diagnosis and management of melanoma in Taiwan | Wu, Chiao-En; YI-HUA LIAO ; Wu, Cheng-Lin; RUOH-FANG YEN ; CHIA-CHI LIN ; Yang, Muh-Hwa; Yen, Chueh-Chuan; Su, Wu-Chou; Yen, Chia-Jui; Chang, Yi-Fang; Wu, Ming-Fang; Yang, Youngsen; Lin, Chen-Yuan; Yang, Wen-Chi; Wang, Hui-Ching; Li, Cheng-Yuan; Ho, Yin-Yu; Chang, Yao-Yu; Wu, Chieh-Shan; Hsu, Hsiu-Cheng; Chen, Kuang-Hua; Huang, Yenlin; Chen, Chih-Jung; Chuang, Pei-Ju; Lai, Yung-Chi; Huang, Yu-Yi; Tseng, Neng-Chuan; Huang, Yi-Ting; CHIA-YU CHU ; Wen-Cheng Chang, John | Journal of the Formosan Medical Association = Taiwan yi zhi | 3 | 0 | |
6 | 2023 | Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors | Bauer, Todd M; Santoro, Armando; CHIA-CHI LIN ; Garrido-Laguna, Ignacio; Joerger, Markus; Greil, Richard; Spreafico, Anna; Yau, Thomas; Goebeler, Maria-Elisabeth; Hütter-Krönke, Marie Luise; Perotti, Antonella; Juif, Pierre-Eric; Lu, Darlene; Barys, Louise; Cremasco, Viviana; Pelletier, Marc; Evans, Helen; Fabre, Claire; Doi, Toshikiko | Journal for immunotherapy of cancer | 3 | ||
7 | 2023 | A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer | Macaulay, Valentine M; Lord, Simon; Hussain, Syed; Maroto, José Pablo; Jones, Robert Hugh; Climent, Miguel Ángel; Cook, Natalie; CHIA-CHI LIN ; Wang, Shian-Shiang; Bianchini, Diletta; Bailey, Mark; Schlieker, Laura; Bogenrieder, Thomas; de Bono, Johann | British journal of cancer | 1 | 1 | |
8 | 2023 | Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer | JHE-CYUAN GUO ; Hsu, Chia-Lang; MIN-SHU HSIEH ; CHIA-CHI LIN ; TA-CHEN HUANG ; HUNG-YANG KUO ; YU-YUN SHAO ; CHIH-HUNG HSU | Thoracic cancer | 0 | 0 | |
9 | 2023 | Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC | Zhou, Qing; Soo, Ross A; Chang, Gee-Chen; Chiu, Chao-Hua; Hayashi, Hidetoshi; Kim, Sang-We; Teraoka, Shunsuke; Goto, Yasushi; Zhou, Jianying; Ho-Fun Lee, Victor; Kim, Dong-Wan; Han, Baohui; Chung Man Ho, James; CHIA-CHI LIN ; Lu, Shun; Polli, Anna; Calella, Anna Maria; Martini, Jean-François; Wong, Chew Hooi; Mok, Tony; Kim, Hye Ryun; Wu, Yi-Long | JTO clinical and research reports | 3 | 0 | |
10 | 2023 | Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study | Oh, Do-Youn; Algazi, Alain; Capdevila, Jaume; Longo, Federico; Miller, Wilson; Chun Bing, Jerry Tan; Bonilla, Carlos Eduardo; Chung, Hyun Cheol; Guren, Tormod K; CHIA-CHI LIN ; Motola-Kuba, Daniel; Shah, Manisha; Hadoux, Julien; Yao, Lili; Jin, Fan; Norwood, Kevin; Lebellec, Loïc | Cancer | 5 | 3 | |
11 | 2022 | Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial | Brose, Marcia S; Robinson, Bruce G; Sherman, Steven I; Jarzab, Barbara; CHIA-CHI LIN ; Vaisman, Fernanda; Hoff, Ana O; Hitre, Erika; Bowles, Daniel W; Sen, Suvajit; Oliver, Jennifer W; Banerjee, Kamalika; Keam, Bhumsuk; Capdevila, Jaume | Cancer | 14 | ||
12 | 2022 | Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study | Simonelli, M; Garralda, E; Eskens, F; Gil-Martin, M; Yen, C-J; Obermannova, R; Chao, Y; Lonardi, S; Melichar, B; Moreno, V; Yu, M-L; Bongiovanni, A; Calvo, E; Rottey, S; Machiels, J-P; Gonzalez-Martin, A; Paz-Ares, L; Chang, C-L; Mason, W; CHIA-CHI LIN ; Reardon, D A; Vieito, M; Santoro, A; Meng, R; Abbadessa, G; Menas, F; Lee, H; Liu, Q; Combeau, C; Ternes, N; Ziti-Ljajic, S; Massard, C | ESMO open | 12 | 8 | |
13 | 2022 | Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors | Wu, Tsung-Che; CHIA-CHI LIN | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 | ||
14 | 2022 | Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI) | Brose, Marcia S; Smit, Johannes W A; CHIA-CHI LIN ; Tori, Masayuki; Bowles, Daniel W; Worden, Francis; Shen, Daniel Hueng-Yuan; Huang, Shih-Ming; Tsai, Hui-Jen; Alevizaki, Maria; Peeters, Robin P; Takahashi, Shunji; Rumyantsev, Pavel; Guan, Rongjin; Babajanyan, Svetlana; Ozgurdal, Kirhan; Sugitani, Iwao; Pitoia, Fabian; Lamartina, Livia | Thyroid : official journal of the American Thyroid Association | 6 | 5 | |
15 | 2022 | Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial | Soo, Ross A; Huat Tan, Eng; Hayashi, Hidetoshi; Seto, Takashi; CHIA-CHI LIN ; Ou, Sai-Hong Ignatius; Kim, Dong-Wan; Liu, Geoffrey; Abbattista, Antonello; Martini, Jean-François; Hooi Wong, Chew; Toffalorio, Francesca; Solomon, Benjamin J | Lung cancer (Amsterdam, Netherlands) | 11 | ||
16 | 2022 | Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy | TA-CHEN HUANG ; Liang C.-W.; Li Y.-I.; GUO, JHE-CYUAN ; CHIA-CHI LIN ; Chen Y.-J.; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of Cancer Research and Clinical Oncology | 2 | 2 | |
17 | 2022 | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors | Chan, Stephen L; Schuler, Martin; Kang, Yoon-Koo; Yen, Chia-Jui; Edeline, Julien; Choo, Su Pin; CHIA-CHI LIN ; Okusaka, Takuji; Weiss, Karl-Heinz; Macarulla, Teresa; Cattan, Stéphane; Blanc, Jean-Frederic; Lee, Kyung-Hun; Maur, Michela; Pant, Shubham; Kudo, Masatoshi; Assenat, Eric; Zhu, Andrew X; Yau, Thomas; Lim, Ho Yeong; Bruix, Jordi; Geier, Andreas; Guillén-Ponce, Carmen; Fasolo, Angelica; Finn, Richard S; Fan, Jia; Vogel, Arndt; Qin, Shukui; Riester, Markus; Katsanou, Vasiliki; Chaudhari, Monica; Kakizume, Tomoyuki; Gu, Yi; Porta, Diana Graus; Myers, Andrea; Delord, Jean-Pierre | Journal of experimental & clinical cancer research : CR | 20 | ||
18 | 2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
19 | 2022 | Immunotherapy in anaplastic thyroid cancer: Case series | SHYANG-RONG SHIH ; Chen, Kuan-Hua; Lin, Kuan-Yu; PAN-CHYR YANG ; KUEN-YUAN CHEN ; CHUN-WEI WANG ; Chun-Nan Chen ; CHIH-FENG LIN ; CHIA-CHI LIN | Journal of the Formosan Medical Association = Taiwan yi zhi | 7 | 6 | |
20 | 2022 | Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies | Shimizu, Toshio; Kuboki, Yasutoshi; CHIA-CHI LIN ; Yonemori, Kan; Yanai, Tomoko; Faller, Douglas V; Dobler, Lwona; Gupta, Neeraj; Sedarati, Farhad; Kim, Kyu-Pyo | Targeted oncology | 0 | 0 | |
21 | 2022 | Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front-line chemotherapy regimens | WEI-LI MA ; CHIA-CHI LIN ; FENG-MING HSU ; JANG-MING LEE ; JIN-SHING CHEN ; YEN-LIN HUANG ; YIH-LEONG CHANG ; Chang, Chin-Hao; CHIH-HSIN YANG | Cancer medicine | 3 | 2 | |
22 | 2022 | Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study | Abdul Razak, Albiruni R; Bauer, Sebastian; Suarez, Cristina; CHIA-CHI LIN ; Quek, Richard; Hütter-Krönke, Marie Luise; Cubedo, Ricardo; Ferretti, Stephane; Guerreiro, Nelson; Jullion, Astrid; Orlando, Elena J; Clementi, Giorgia; Sand Dejmek, Janna; Halilovic, Ensar; Fabre, Claire; Blay, Jean-Yves; Italiano, Antoine | Clinical cancer research : an official journal of the American Association for Cancer Research | 21 | ||
23 | 2022 | Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia | Stein, Eytan M; DeAngelo, Daniel J; Chromik, Jörg; Chatterjee, Manik; Bauer, Sebastian; CHIA-CHI LIN ; Suarez, Cristina; de Vos, Filip; Steeghs, Neeltje; Cassier, Philippe A; Tai, David; Kiladjian, Jean-Jacques; Yamamoto, Noboru; Mous, Rogier; Esteve, Jordi; Minami, Hironobu; Ferretti, Stephane; Guerreiro, Nelson; Meille, Christophe; Radhakrishnan, Rajkumar; Pereira, Bernard; Mariconti, Luisa; Halilovic, Ensar; Fabre, Claire; Carpio, Cecilia | Clinical cancer research : an official journal of the American Association for Cancer Research | 29 | ||
24 | 2022 | Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma | JHE-CYUAN GUO ; CHIA-CHI LIN ; Hsu, Chia-Lang; TA-CHEN HUANG ; HUNG-YANG KUO ; Lin, Chen-Yuan; Lien, Ming-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Esophagus : official journal of the Japan Esophageal Society | 0 | 0 | |
25 | 2022 | First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma | Italiano A.; Cassier P.A.; CHIA-CHI LIN ; Alanko T.; Peltola K.J.; Gazzah A.; Shiah H.-S.; Calvo E.; Cervantes A.; Roda D.; Tosi D.; Gao B.; Millward M.; Warburton L.; Tanner M.; Englert S.; Lambert S.; Parikh A.; Afar D.E.; Vosganian G.; Moreno V. | Cancer Immunology, Immunotherapy | 5 | 5 | |
26 | 2022 | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study | Zucali P.A.; CHIA-CHI LIN ; Carthon B.C.; Bauer T.M.; Tucci M.; Italiano A.; Iacovelli R.; Su W.-C.; Massard C.; Saleh M.; Daniele G.; Greystoke A.; Gutierrez M.; Pant S.; YING-CHUN SHEN ; Perrino M.; Meng R.; Abbadessa G.; Lee H.; Dong Y.; Chiron M.; Wang R.; Loumagne L.; L?pine L.; De Bono J. | Journal for ImmunoTherapy of Cancer | 25 | 18 | |
27 | 2022 | A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies | Shimizu T.; Kuboki Y.; CHIA-CHI LIN ; Yonemori K.; Yanai T.; Faller D.V.; Dobler L.; Gupta N.; Sedarati F.; Kim K.-P. | Targeted Oncology | 5 | 5 | |
28 | 2021 | Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites | GUO, JHE-CYUAN ; Lin, Chen Yuan; CHIA-CHI LIN ; TA-CHEN HUANG ; Lien, Ming Yu; LI-CHUN LU ; HUNG-YANG KUO ; CHIH-HUNG HSU | ONCOLOGY (United States) | 1 | 1 | |
29 | 2021 | Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer | Dziadziuszko, Rafal; Krebs, Matthew G; De Braud, Filippo; Siena, Salvatore; Drilon, Alexander; Doebele, Robert C; Patel, Manish R; Cho, Byoung Chul; Liu, Stephen V; Ahn, Myung-Ju; Chiu, Chao-Hua; Farago, Anna F; CHIA-CHI LIN ; Karapetis, Christos S; Li, Yu-Chung; Day, Bann-Mo; Chen, David; Wilson, Timothy R; Barlesi, Fabrice | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 80 | 57 | |
30 | 2021 | Endoscopic ultrasound ablation in a patient with multiple metastatic pancreatic tumors from adrenocorticotropic hormone-producing thymic neuroendocrine neoplasm | Chang, Ling-Kai; Chen, Kuan-Chih; MEI-FANG CHENG ; CHIA-CHI LIN ; HSIU-PO WANG ; Sung, Chia-Tung; Chen, Jou-Ho; RUOH-FANG YEN ; CHIA-LIN HSU ; SHYANG-RONG SHIH | Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society | 2 | 2 | |
31 | 2021 | Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves' Orbitopathy | SHYANG-RONG SHIH ; SHU-LANG LIAO ; Shih, Chih-Wei; YI-HSUAN WEI ; Lu, Ting-Xuan; Chou, Chien-Hsiang; Yen, Er-Yen; YI-CHENG CHANG ; CHIA-CHI LIN ; Chi, Yu-Chiao; WEI-SHIUNG YANG ; FENG-CHIAO TSAI | Ocular immunology and inflammation | 4 | 4 | |
32 | 2021 | Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC | BIN-CHI LIAO ; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHING-YAO YANG ; TZU-HSIU TSAI ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Soo, Ross A; CHIH-HSIN YANG | JTO clinical and research reports | 2 | 0 | |
33 | 2021 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia | CHIA-CHI LIN ; Doi T.; Muro K.; Hou M.-M.; Esaki T.; Hara H.; Chung H.C.; Helwig C.; Dussault I.; Osada M.; Kondo S. | Targeted Oncology | 18 | 12 | |
34 | 2021 | Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors | Shiah H.-S.; Chiang N.-J.; CHIA-CHI LIN ; Yen C.-J.; Tsai H.-J.; Wu S.-Y.; Su W.-C.; Chang K.-Y.; Wang C.-C.; Chang J.-Y.; Chen L.-T. | Oncologist | 2 | 0 | |
35 | 2021 | Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: The PACT phase Ia/Ib trial | Patnaik A.; Yap T.A.; Chung H.C.; de Miguel M.J.; Bang Y.-J.; CHIA-CHI LIN ; Su W.-C.; Italiano A.; Chow K.H.; Szpurka A.M.; Yu D.; Zhao Y.; Carlsen M.; Schmidt S.; Vangerow B.; Gandhi L.; Xu X.; Bendell J. | Clinical Cancer Research | 23 | 17 | |
36 | 2021 | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | Park K.; Tan D.S.W.; Su W.-C.; Cho B.C.; Kim S.-W.; Lee K.H.; Wang C.-C.; Seto T.; Huang D.C.-L.; Jung H.H.; Hsu M.-C.; Bogenrieder T.; CHIA-CHI LIN | JTO Clinical and Research Reports | 4 | 0 | |
37 | 2021 | Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors | Curigliano G.; Gelderblom H.; Mach N.; Doi T.; Tai D.; Forde P.M.; Sarantopoulos J.; Bedard P.L.; CHIA-CHI LIN ; Stephen Hodi F.; Wilgenhof S.; Santoro A.; Sabatos-Peyton C.A.; Longmire T.A.; Xyrafas A.; Sun H.; Gutzwiller S.; Manenti L.; Naing A. | Clinical Cancer Research | 143 | 108 | |
38 | 2021 | Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors | Takahashi S.; Karayama M.; Takahashi M.; Watanabe J.; Minami H.; Yamamoto N.; Kinoshita I.; CHIA-CHI LIN ; Im Y.-H.; Achiwa I.; Kamiyama E.; Okuda Y.; Lee C.; Bang Y.-J. | Clinical Cancer Research | 14 | 11 | |
39 | 2021 | Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors | Lewis J.H.; Gelderblom H.; van de Sande M.; Stacchiotti S.; Healey J.H.; Tap W.D.; Wagner A.J.; Pousa A.L.; Druta M.; CHIA-CHI LIN ; Baba H.A.; Choi Y.; Wang Q.; Shuster D.E.; Bauer S. | Oncologist | 23 | 21 | |
40 | 2021 | Clinical development of colony-stimulating factor 1 receptor (Csf1r) inhibitors | CHIA-CHI LIN | Journal of Immunotherapy and Precision Oncology | 21 | 0 | |
41 | 2021 | Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan | Yin O.; Iwata H.; CHIA-CHI LIN ; Tamura K.; Watanabe J.; Wada R.; Kastrissios H.; AbuTarif M.; Garimella T.; Lee C.; Zhang L.; Shahidi J.; LaCreta F. | Clinical Pharmacology and Therapeutics | 22 | 15 | |
42 | 2021 | Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial | Brose M.S.; Robinson B.; Sherman S.I.; Krajewska J.; CHIA-CHI LIN ; Vaisman F.; Hoff A.O.; Hitre E.; Bowles D.W.; Hernando J.; Faoro L.; Banerjee K.; Oliver J.W.; Keam B.; Capdevila J. | The Lancet Oncology | 127 | 101 | |
43 | 2021 | Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study | Subbiah V.; Hu M.I.; Wirth L.J.; Schuler M.; Mansfield A.S.; Curigliano G.; Brose M.S.; Zhu V.W.; Leboulleux S.; Bowles D.W.; Baik C.S.; Adkins D.; Keam B.; Matos I.; Garralda E.; Gainor J.F.; Lopes G.; CHIA-CHI LIN ; Godbert Y.; Sarker D.; Miller S.G.; Clifford C.; Zhang H.; Turner C.D.; Taylor M.H. | The Lancet Diabetes and Endocrinology | 190 | 140 | |
44 | 2021 | Safety and Antitumor Activity of a-PD-L1 Antibody as Monotherapy or in Combination witha-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors | Hollebecque A.; Chung H.C.; Miguel M.J.D.; Italiano A.; MacHiels J.-P.; CHIA-CHI LIN ; Dhani N.C.; Peeters M.; Moreno V.; Su W.-C.; Chow K.H.; Galvao V.R.; Carlse M.; Yu D.; Szpurka A.M.; Zhao Y.; Schmidt S.L.; Gandhi L.; Xu X.; Bang Y.-J. | Clinical Cancer Research | 31 | 21 | |
45 | 2021 | Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia—Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium | Shimizu T.; Kim D.-W.; Loong H.H.; CHIA-CHI LIN ; Ng M.C.H.; Yamamoto N.; Ma B.; Tan D.S.W. | Asia-Pacific Journal of Clinical Oncology | 2 | 1 | |
46 | 2020 | Novel trial designs for early phase clinical trials | CHIA-CHI LIN | Phase I Oncology Drug Development | |||
47 | 2020 | Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial | Drakaki A.; Kirby C.J.; Van Der Heijden M.S.; Petrylak D.P.; Powles T.; Chi K.N.; Fl?chon A.; Necchi A.; G?czi L.; Lee J.-L.; Gakis G.; Bracarda S.; Chowdhury S.; CHIA-CHI LIN ; Keizman D.; Vaishampayan U.N.; Zimmermann A.H.; Bell-Mcguinn K.; Castellano D. | Bladder Cancer | 2 | 2 | |
48 | 2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 33 | 30 | |
49 | 2020 | Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial | Paz-Ares L.; Kim T.M.; Vicente D.; Felip E.; Lee D.H.; Lee K.H.; CHIA-CHI LIN ; Flor M.J.; Di Nicola M.; Alvarez R.M.; Dussault I.; Helwig C.; Ojalvo L.S.; Gulley J.L.; Cho B.C. | Journal of Thoracic Oncology | 112 | 101 | |
50 | 2020 | Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Chia-Chi Hsu; BIN-CHI LIAO ; Wei-Hsun Hsu; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 55 | 49 | |
51 | 2020 | Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors | Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; CHIA-CHI LIN ; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. | Molecular Cancer Therapeutics | 16 | 14 | |
52 | 2020 | Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib | CHING-YAO YANG ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Liu, Yi-Nan; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; BIN-CHI LIAO ; Hsu, Chia-Chi; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 15 | 15 | |
53 | 2020 | A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies | Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; CHIA-CHI LIN ; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. | Investigational New Drugs | 15 | 14 | |
54 | 2020 | Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) | Bang Y.-J.; Golan T.; Dahan L.; Fu S.; Moreno V.; Park K.; Geva R.; De Braud F.; Wainberg Z.A.; Reck M.; Goff L.; Laing N.; Mi G.; Oliveira J.M.; Wasserstrom H.; CHIA-CHI LIN | European Journal of Cancer | 86 | 80 | |
55 | 2020 | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts | Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. | Cancer Science | 43 | 35 | |
56 | 2020 | PD-1 blockade in anaplastic thyroid carcinoma | Capdevila J.; Wirth L.J.; Ernst T.; Aix S.P.; CHIA-CHI LIN ; Ramlau R.; Butler M.O.; Delord J.-P.; Gelderblom H.; Ascierto P.A.; Fasolo A.; F?hrer D.; H?tter-Kr?nke M.L.; Forde P.M.; Wrona A.; Santoro A.; Sadow P.M.; Szpakowski S.; Wu H.; Bostel G.; Faris J.; Cameron S.; Varga A.; Taylor M. | Journal of Clinical Oncology | 165 | 126 | |
57 | 2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 39 | 36 | |
58 | 2020 | Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study | CHIA-CHI LIN ; Yang T.-S.; Yen C.-J.; Cheng R.; Liu J.; CHIUN HSU | Oncologist | 5 | 4 | |
59 | 2020 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours | de Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG | British Journal of Cancer | 20 | 17 | |
60 | 2020 | Rational combination with an immunotherapy backbone in genitourinary cancers | JHE-CYUAN GUO ; CHIA-CHI LIN | Urological Science | 3 | 3 | |
61 | 2020 | Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors | Desai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. | Journal for ImmunoTherapy of Cancer | 87 | 73 | |
62 | 2020 | Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer | Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; CHIA-CHI LIN ; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. | Lung Cancer | 14 | 12 | |
63 | 2020 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial | Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Fl?chon A.; Bamias A.; Yu E.Y.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J.; Lee Y.-G.; Vazquez Cort?s L.; Lorena Urzua Flores C.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; van der Heijden M.S.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Gajate Borau P.; Grande E.; Matsubara N.; Delgado Mignorance J.I.; Su Y.-L.; Li J.-R.; Lin C.-L.; CHIA-CHI LIN ; Yeh S.-P.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Alekseev B.; Sinielnikov I.; Crabb S.J.; Syndikus I.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.W.; Pan C.X.; Schwarz J.K.; Necchi A.; Cultrera J.L.; Acs P.I.; Hainsworth J.D.; Herms B.T.; Lawler W.E.; Lowe T.E.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S. | The Lancet Oncology | 59 | 51 | |
64 | 2020 | A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors | Naing A.; Gainor J.F.; Gelderblom H.; Forde P.M.; Butler M.O.; CHIA-CHI LIN ; Sharma S.; Ochoa De Olza M.; Varga A.; Taylor M.; Schellens J.H.M.; Wu H.; Sun H.; Silva A.P.; Faris J.; Mataraza J.; Cameron S.; Bauer T.M. | Journal for ImmunoTherapy of Cancer | 56 | 46 | |
65 | 2020 | An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer | Bible K.C.; Menefee M.E.; CHIA-CHI LIN ; Millward M.J.; Maples W.J.; Goh B.C.; Karlin N.J.; Kane M.A.; Adkins D.R.; Molina J.R.; Donehower R.C.; Lim W.-T.; Flynn P.J.; Richardson R.L.; Traynor A.M.; Rubin J.; Lorusso P.M.; Smallridge R.C.; Burton J.K.; Suman V.J.; Kumar A.; Voss J.S.; Rumilla K.M.; Kipp B.R.; Chintakuntlawar A.V.; Harris P.; Erlichman C. | Thyroid | 16 | 13 | |
66 | 2020 | Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials | Drilon A.; Siena S.; Dziadziuszko R.; Barlesi F.; Krebs M.G.; Shaw A.T.; de Braud F.; Rolfo C.; Ahn M.-J.; Wolf J.; Seto T.; Cho B.C.; Patel M.R.; Chiu C.-H.; John T.; Goto K.; Karapetis C.S.; Arkenau H.-T.; Kim S.-W.; Ohe Y.; Li Y.-C.; Chae Y.K.; Chung C.H.; Otterson G.A.; Murakami H.; CHIA-CHI LIN ; Tan D.S.W.; Prenen H.; Riehl T.; Chow-Maneval E.; Simmons B.; Cui N.; Johnson A.; Eng S.; Wilson T.R.; Doebele R.C. | The Lancet Oncology | 326 | 250 | |
67 | 2020 | An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC | Zhu, Viola W; YEN-TING LIN ; Kim, Dong-Wan; Loong, Herbert H; Nagasaka, Misako; To, Hao; Ang, Yvonne Li-En; Ock, Chan-Young; Tchekmedyian, Nishan; Ou, Sai-Hong Ignatius; Syn, Nicholas L; Reungwetwattana, Thanyanan; CHIA-CHI LIN ; Soo, Ross A | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 47 | 36 | |
68 | 2020 | Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma | Si L.; Zhang X.; Shin S.J.; Fan Y.; CHIA-CHI LIN ; Kim T.M.; Dechaphunkul A.; Maneechavakajorn J.; Wong C.S.; Ilankumaran P.; Lee D.-Y.; Gasal E.; Li H.; Guo J. | European Journal of Cancer | 13 | 8 | |
69 | 2019 | Nuclear Factor-κB Overexpression is Correlated with Poor Outcomes after Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer | CHIANG, YUN ; Wang, Chung-Chieh; YU-CHIEH TSAI ; CHAO-YUAN HUANG ; YEONG-SHIAU PU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG | Journal of clinical medicine | 8 | 7 | |
70 | 2019 | Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors | JHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU | Anticancer research | 28 | 29 | |
71 | 2019 | A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas | CHIA-CHI LIN ; Arkenau H.-T.; Lu S.; Sachdev J.; de Castro Carpe?o J.; Mita M.; Dziadziuszko R.; Su W.-C.; Bobilev D.; Hughes L.; Chan J.; Zhang Z.-Y.; Weiss G.J. | British Journal of Cancer | 17 | 12 | |
72 | 2019 | An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma | El Dika I.; Lim H.Y.; Yong W.P.; CHIA-CHI LIN ; Yoon J.-H.; Modiano M.; Freilich B.; Choi H.J.; Chao T.-Y.; Kelley R.K.; Brown J.; Knox J.; Ryoo B.-Y.; Yau T.; Abou-Alfa G.K. | Oncologist | 75 | 59 | |
73 | 2019 | Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma | Ta-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 8 | 6 | |
74 | 2019 | Challenges of the phase I drug development in non-small cell lung cancer | CHIA-CHI LIN | Chinese Clinical Oncology | 7 | 8 | |
75 | 2019 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial | Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; CHIA-CHI LIN ; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I. | The Lancet Oncology | 234 | 173 | |
76 | 2019 | ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non–small-cell lung cancer | Shaw A.T.; Solomon B.J.; Besse B.; Bauer T.M.; CHIA-CHI LIN ; Soo R.A.; Riely G.J.; Ignatius Ou S.-H.; Clancy J.S.; Li S.; Abbattista A.; Thurm H.; Satouchi M.; Camidge D.R.; Kao S.; Chiari R.; Gadgeel S.M.; Felip E.; Martini J.-F. | Journal of Clinical Oncology | 285 | 208 | |
77 | 2019 | Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study | WEI-LI MA ; CHIA-CHI LIN ; FENG-MING HSU ; JANG-MING LEE ; JIN-SHING CHEN ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Chao Y.-T.; Chang C.-H.; CHIH-HSIN YANG | Clinical Lung Cancer | 10 | 9 | |
78 | 2019 | Should we design clinical trials differently in the era of cancer immunotherapy? | CHIA-CHI LIN | Journal of Immunotherapy and Precision Oncology | 3 | 0 | |
79 | 2019 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer | Mehnert J.M.; Varga A.; Brose M.S.; Aggarwal R.R.; CHIA-CHI LIN ; Prawira A.; De Braud F.; Tamura K.; Doi T.; Piha-Paul S.A.; Gilbert J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Keam B. | BMC Cancer | 135 | 108 | |
80 | 2019 | Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors | Doi T.; CHIH-HSIN YANG ; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; CHIA-CHI LIN | Targeted Oncology | 22 | 14 | |
81 | 2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
82 | 2019 | Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment | SHAO-LUN LU ; Feng-Ming Hsu ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YIH-LEONG CHANG ; MIN-SHU HSIEH ; CHIA-HSIEN CHENG | European Journal of Surgical Oncology | 10 | 7 | |
83 | 2018 | A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma | SHIH-HUNG YANG ; YU-YUN SHAO ; CHIA-CHI LIN ; SUNG-HSIN KUO ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 3 | 2 | |
84 | 2018 | Management of Toxicities of Targeted Therapies | CHIH-HSIN YANG ; CHIA-CHI LIN ; CHIA-YU CHU | IASLC Thoracic Oncology | 4 | 0 | |
85 | 2018 | Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan | SHU-YUNG LIN ; Yang C.-Y.; BIN-CHI LIAO ; CHAO-CHI HO ; WEI-YU LIAO ; KUAN-YU CHEN ; TZU-HSIU TSAI ; CHIA-LIN HSU ; Hsu W.-H.; KANG-YI SU ; YIH-LEONG CHANG ; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | Journal of Cancer | 40 | 41 | |
86 | 2018 | Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study | CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHAO-CHI HO ; WEI-YU LIAO ; JIH-HSIANG LEE ; TZU-HSIU TSAI ; KANG-YI SU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Bai Y.-Y.; DE-RUI HUANG ; Thress K.S.; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 120 | 109 | |
87 | 2018 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012 | Mehra R.; Seiwert T.Y.; Gupta S.; Weiss J.; Gluck I.; Eder J.P.; Burtness B.; Tahara M.; Keam B.; Kang H.; Muro K.; Geva R.; Chung H.C.; CHIA-CHI LIN ; Aurora-Garg D.; Ray A.; Pathiraja K.; Cheng J.; Chow L.Q.M.; Haddad R. | British Journal of Cancer | 303 | 256 | |
88 | 2018 | Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease? | PEI-MING HUANG ; Feng-Ming Hsu ; CHIA-CHI LIN ; Hsu C.-H.; CHIA-HSIEN CHENG ; JANG-MING LEE | Digestive Surgery | 4 | 4 | |
89 | 2018 | Using Ion Torrent sequencing to study genetic mutation profiles of fatal thyroid cancers | JIN-YING LU ; WERN-CHERNG CHENG ; KUEN-YUAN CHEN ; CHIA-CHI LIN ; CHING-CHUNG CHANG ; KUAN-TING KUO ; PEI-LUNG CHEN | Journal of the Formosan Medical Association | 3 | 1 | |
90 | 2018 | TAK-264 (MLN0264) in previously treated Asian patients with advanced gastrointestinal carcinoma expressing guanylyl cyclase C: Results from an open-label, non-randomized phase 1 study | Bang Y.-J.; Takano T.; CHIA-CHI LIN ; Fasanmade A.; Yang H.; Danaee H.; Asato T.; Kalebic T.; Wang H.; Doi T. | Cancer Research and Treatment | 7 | 6 | |
91 | 2018 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | Solomon B.J.; Besse B.; Bauer T.M.; Felip E.; Soo R.A.; Camidge D.R.; Chiari R.; Bearz A.; CHIA-CHI LIN ; Gadgeel S.M.; Riely G.J.; Tan E.H.; Seto T.; James L.P.; Clancy J.S.; Abbattista A.; Martini J.-F.; Chen J.; Peltz G.; Thurm H.; Ignatius Ou S.-H.; Shaw A.T. | The Lancet Oncology | 583 | 458 | |
92 | 2018 | Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients | Wu T.-H.; Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; WEI-YU LIAO ; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Clinical Lung Cancer | 17 | 17 | |
93 | 2018 | Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy | JHE-CYUAN GUO ; CHIA-CHI LIN ; Ta-Chen Huang ; PEI-MING HUANG ; HUNG-YANG KUO ; Chang C.-H.; CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU ; JANG-MING LEE | Anticancer Research | 12 | 11 | |
94 | 2018 | Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors | BIN-CHI LIAO ; Bai Y.-Y; JIH-HSIANG LEE ; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 11 | 9 | |
95 | 2018 | Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Opinion on Pharmacotherapy | 5 | 5 | |
96 | 2018 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 | Tahara M.; Muro K.; Hasegawa Y.; Chung H.C.; CHIA-CHI LIN ; Keam B.; Takahashi K.; Cheng J.D.; Bang Y.-J. | Cancer Science | 42 | 42 | |
97 | 2018 | Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma | Yang P.-C.; JHE-CYUAN GUO ; MIN-SHU HSIEH ; CHIA-CHI LIN ; CHIH-HUNG HSU | Journal of Thoracic Oncology | 6 | 4 | |
98 | 2017 | New data on clinical decisions in NSCLC patients with uncommon EGFR mutations | Wu T.; Hsiue E.H.; JIH-HSIANG LEE ; Chia-Chi Lin ; CHIH-HSIN YANG | Expert Review of Respiratory Medicine | 15 | 14 | |
99 | 2017 | Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | BIN-CHI LIAO ; Chia-Chi Lin ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Lung Cancer | 38 | 35 | |
100 | 2017 | Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Oncology Reports | 19 | 19 | |
101 | 2017 | Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 25 | 25 | |
102 | 2017 | Optimal usage of radium-223 in metastatic castration-resistant prostate cancer | Cha T.-L.; Wu T.T.-L.; Vogelzang N.J.; CHAO-YUAN HUANG ; Huang S.-P.; CHIA-CHI LIN ; Ou Y.-C.; Pang S.-T.; Shen D.H.-Y.; Wu W.-J.; Chang W.Y.-H. | Journal of the Formosan Medical Association | 15 | 14 | |
103 | 2017 | Timing of multikinase inhibitor initiation in differentiated thyroid cancer | Brose M.S.; Smit J.; CHIA-CHI LIN ; Pitoia F.; Fellous M.; De Sanctis Y.; Schlumberger M.; Tori M.; Sugitani I. | Endocrine-Related Cancer | 29 | 27 | |
104 | 2017 | Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial | Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.; Fl?chon A.; Bamias A.; Yu E.Y.; Lee Y.-G.; Cort?s L.V.; Flores C.L.U.; Blaisse R.J.B.; Erdkamp F.L.G.; Aarts M.J.B.; Wojcik-Tomaszewska J.; Tomczak P.; Sikora-Kupis B.; Schenker M.; van der Heijden M.S.; Herzal A.A.; Udrea A.A.; Karlov P.; Fomkin R.; Pulido E.G.; Mignorance J.I.D.; Gauna D.C.; Rodr?guez-Vida A.; Su Y.-L.; Lin C.-L.; Matsubara N.; CHIA-CHI LIN ; Yeh S.-P.; ?i?in I.; Erman M.; Urun Y.; Golovko Y.; Bondarenko I.; Sinielnikov I.; Crabb S.; Syndikus I.; Alekseev B.; Huddart R.; Sundar S.; Chowdhury S.; Sarwar N.; Flaig T.; Pan C.X.; Schwarz J.; Cultrera J.; Hainsworth J.; Herms B.; Necchi A.; Lawler W.; Lowe T.; Tagawa S.; Aragon-Ching J.; Vaishampayan U.; G?czi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Hegemann M.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; del Muro X.G.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Widau R.C.; Liepa A.M.; Walgren R.A.; Hamid O.; Zimmermann A.H.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Ng S.S.W.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Flechon A.; Culine S.; Becht C.; Niegisch G.; St?ckle M.; Grimm M.-O.; Gakis G.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; R?v?sz J.; Geczi L.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid D.; Scagliotti G.V.; Bracarda S.; Massari F.; Osawa T.; Miyajima N.; Shinohara N.; Fukuta F.; Ohyama C.; Obara W.; Yamashita S.; Tomita Y.; Kawai K.; Fukasawa S.; Oyama M.; Yonese J.; Nagata M.; Uemura M.; Nishimura K.; Kawakita M.; Tsunemori H.; Hashine K.; Inokuchi J.; Yokomizo A.; Nagamori S.; Lee H.J.; Park S.H.; Rha S.Y.; Kim Y.J. | The Lancet | 139 | 122 | |
105 | 2017 | A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement | YUN CHIANG ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Chia-Chi Lin ; CHIH-HUNG HSU ; ANN-LII CHENG ; YEONG-SHIAU PU | Journal of the Formosan Medical Association | 7 | 6 | |
106 | 2017 | Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component | CHIH-HSIN YANG ; Ahn M.-J.; Kim D.-W.; Ramalingam S.S.; Sequist L.V.; Su W.-C.; Kim S.-W.; Kim J.-H.; Planchard D.; Felip E.; Blackhall F.; Haggstrom D.; Yoh K.; Novello S.; Gold K.; Hirashima T.; Chia-Chi Lin ; Mann H.; Cantarini M.; Ghiorghiu S.; Jänne P.A. | Journal of Clinical Oncology | 459 | 443 | |
107 | 2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 85 | 67 | |
108 | 2017 | A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer | Reynolds K.L.; Bedard P.L.; Lee S.-H.; Chia-Chi Lin ; Tabernero J.; Alsina M.; Cohen E.; Baselga J.; Blumenschein G.; Graham D.M.; Garrido-Laguna I.; Juric D.; Sharma S.; Salgia R.; Seroutou A.; Tian X.; Fernandez R.; Morozov A.; Sheng Q.; Ramkumar T.; Zubel A.; Bang Y.-J. | BMC Cancer | 22 | 21 | |
109 | 2016 | Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer | Chen, Kai-Lung; CHIA-CHI LIN ; YUNG-TSU CHO ; Yang, Che-Wen; YI-SHUAN SHEEN ; Tsai, Hsiao-En; CHIA-YU CHU | JAMA Dermatology | 29 | 20 | |
110 | 2016 | 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs | BIN-CHI LIAO ; Bai Y.-Y.; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 1 | 1 | |
111 | 2016 | Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors | BIN-CHI LIAO ; CHIA-CHI LIN ; JIH-HSIANG LEE ; CHIH-HSIN YANG | Journal of Biomedical Science | 43 | 37 | |
112 | 2016 | Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer | Hsiue E.H.-C; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Review of Molecular Diagnostics | 15 | 14 | |
113 | 2016 | Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study | CHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. | Journal of Thoracic Oncology | 22 | 20 | |
114 | 2016 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Muro K.; Chung H.C.; Shankaran V.; Geva R.; Catenacci D.; Gupta S.; Eder J.P.; Golan T.; Le D.T.; Burtness B.; McRee A.J.; CHIA-CHI LIN ; Pathiraja K.; Lunceford J.; Emancipator K.; Juco J.; Koshiji M.; Bang Y.-J. | The Lancet Oncology | 895 | 787 | |
115 | 2016 | Obesity and outcomes in patients with metastatic urothelial carcinoma | Leiter A.; Doucette J.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Bamias A.; Oh W.K.; Galsky M.D. | Bladder Cancer | 6 | 0 | |
116 | 2016 | Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: Results of an international randomized phase II trial (JASINT1) | De Santis M.; Wiechno P.J.; Bellmunt J.; Lucas C.; Su W.-C.; Albiges L.; CHIA-CHI LIN ; Senkus-Konefka E.; Flechon A.; Mourey L.; Necchi A.; Loidl W.C.; Retz M.M.; Vaissi?re N.; Culine S. | Annals of Oncology | 46 | 39 | |
117 | 2016 | Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort | Chow L.Q.M.; Haddad R.; Gupta S.; Mahipal A.; Mehra R.; Tahara M.; Berger R.; Eder J.P.; Burtness B.; Lee S.-H.; Keam B.; Kang H.; Muro K.; Weiss J.; Geva R.; CHIA-CHI LIN ; Chung H.C.; Meister A.; Dolled-Filhart M.; Pathiraja K.; Cheng J.D.; Seiwert T.Y. | Journal of Clinical Oncology | 663 | 141 | |
118 | 2016 | Safety of gefitinib in non-small cell lung cancer treatment | Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Opinion on Drug Safety | 19 | 15 | |
119 | 2016 | Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4) | Motzer R.J.; Alyasova A.; Ye D.; Karpenko A.; Li H.; Alekseev B.; Xie L.; Kurteva G.; Kowalyszyn R.; Karyakin O.; Neron Y.; Cosgriff T.; Collins L.; Brechenmacher T.; CHIA-CHI LIN ; Morgan L.; Yang L. | Annals of Oncology | 35 | 34 | |
120 | 2016 | Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors | Minami H.; Ando Y.; Ma B.B.Y.; Hsiang Lee J.; Momota H.; Fujiwara Y.; Li L.; Fukino K.; Ito K.; Tajima T.; Mori A.; CHIA-CHI LIN | Cancer Science | 17 | 15 | |
121 | 2015 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose | Venkatakrishnan K.; Kim T.M.; CHIA-CHI LIN ; Thye L.S.; Chng W.J.; Ma B.; Chen M.H.; Zhou X.; Liu H.; Kelly V.; Kim W.S. | Investigational New Drugs | 26 | 27 | |
122 | 2015 | Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma | JHE-CYUAN GUO ; Ta-Chen Huang ; CHIA-CHI LIN ; MIN-SHU HSIEH ; Chang C.-H.; PEI-MING HUANG ; JANG-MING LEE ; Feng-Ming Hsu ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of Thoracic Oncology | 15 | 16 | |
123 | 2015 | RECORD-2: Phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma | Ravaud A.; Barrios C.H.; Alekseev B.; Tay M.-H.; Agarwala S.S.; Yalcin S.; CHIA-CHI LIN ; Roman L.; Shkolnik M.; Anak O.; Gogov S.; Pelov D.; Louveau A.-L.; Melichar B. | Annals of Oncology | 66 | 57 | |
124 | 2015 | Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Opinion in Oncology | 122 | 109 | |
125 | 2015 | Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma | CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Feng-Ming Hsu | Radiotherapy and Oncology | 10 | 8 | |
126 | 2015 | Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy | BIN-CHI LIAO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG | Therapeutic Advances in Medical Oncology | 16 | 16 | |
127 | 2015 | Systematic review and network meta-analysis: Neoadjuvant chemoradiotherapy for locoregional esophageal cancer | Ta-Chen Huang ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-KANG TU | Japanese Journal of Clinical Oncology | 30 | 27 | |
128 | 2015 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis | BIN-CHI LIAO ; JIH-HSIANG LEE ; CHIA-CHI LIN ; YA-FANG CHEN ; Chang C.-H.; CHAO-CHI HO ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 141 | 113 | |
129 | 2014 | First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial | CHIH-HSIN YANG ; Kang J.H.; Mok T.; Ahn M.-J.; Srimuninnimit V.; CHIA-CHI LIN ; Kim D.-W.; Tsai C.-M.; Barraclough H.; Altug S.; Orlando M.; Park K. | European Journal of Cancer | 41 | 40 | |
130 | 2014 | A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors | Ghamande S.; CHIA-CHI LIN ; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; CHIH-HSIN YANG ; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S. | Investigational New Drugs | 23 | 15 | |
131 | 2014 | Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy | Galsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Pond G.; Godbold J.; Oh W.K.; Bamias A. | Urologic Oncology: Seminars and Original Investigations | 11 | 4 | |
132 | 2014 | Phase II results of dovitinib (TKI258) in patients with metastatic renal cell cancer | Escudier B.; Gr?nwald V.; Ravaud A.; Ou Y.-C.; Castellano D.; CHIA-CHI LIN ; Gschwend J.E.; Harzstark A.; Beall S.; Pirotta N.; Squires M.; Shi M.; Angevin E. | Clinical Cancer Research | 49 | 44 | |
133 | 2014 | An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer | Stadler W.M.; Vaughn D.J.; Sonpavde G.; Vogelzang N.J.; Tagawa S.T.; Petrylak D.P.; Rosen P.; CHIA-CHI LIN ; Mahoney J.; Modi S.; Lee P.; Ernstoff M.S.; Su W.-C.; Spira A.; Pilz K.; Vinisko R.; Schloss C.; Fritsch H.; Zhao C.; Carducci M.A. | Cancer | 78 | 73 | |
134 | 2014 | Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer | Galsky M.D.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A. | Urologic Oncology: Seminars and Original Investigations | 22 | 7 | |
135 | 2014 | Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer | JIH-HSIANG LEE ; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; YEUN-CHUNG CHANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIA-CHI LIN ; KUAN-YU CHEN ; CHAO-CHI HO ; WEI-YU LIAO ; PAN-CHYR YANG ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 44 | 35 | |
136 | 2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 63 | 64 | |
137 | 2013 | Reply to S. Vale | CHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU | Journal of Clinical Oncology | 0 | 0 | |
138 | 2013 | Scalp melanoma in a woman with LEOPARD syndrome: Possible implication of PTPN11 signaling in melanoma pathogenesis | Cheng Y.-P.; HSIEN-YI CHIU ; Hsiao T.-L.; Hsiao C.-H.; CHIA-CHI LIN ; YI-HUA LIAO | Journal of the American Academy of Dermatology | 15 | 11 | |
139 | 2013 | Case report | CHIA-CHI LIN ; JANN-YUAN WANG ; YEONG-SHIAU PU | Journal of Clinical Oncology | 6 | 7 | |
140 | 2013 | Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy | Galsky M.D.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A. | Cancer | 9 | 9 | |
141 | 2013 | Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma | Angevin E.; Lopez-Martin J.A.; CHIA-CHI LIN ; Gschwend J.E.; Harzstark A.; Castellano D.; Soria J.-C.; Sen P.; Chang J.; Shi M.; Kay A.; Escudier B. | Clinical Cancer Research | 113 | 105 | |
142 | 2013 | Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial | Smith D.C.; Smith M.R.; Sweeney C.; Elfiky A.A.; Logothetis C.; Corn P.G.; Vogelzang N.J.; Small E.J.; Harzstark A.L.; Gordon M.S.; Vaishampayan U.N.; Haas N.B.; Spira A.I.; Lara Jr. P.N.; CHIA-CHI LIN ; Srinivas S.; Sella A.; Sch?ffski P.; Scheffold C.; Weitzman A.L.; Hussain M. | Journal of Clinical Oncology | 377 | 346 | |
143 | 2013 | The impact of gender on outcomes in patients with metastatic urothelial carcinoma | Haines L.; Bamias A.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.H.; Moshier E.; Sonpavde G.; Godbold J.; Oh W.K.; Galsky M.D. | Clinical Genitourinary Cancer | 20 | 16 | |
144 | 2013 | Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy | Galsky M.D.; Moshier E.; Krege S.; CHIA-CHI LIN ; Hahn N.; Ecke T.; Sonpavde G.; Godbold J.; Oh W.K.; Bamias A. | Cancer | 80 | 72 | |
145 | 2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | HSIANG-FONG KAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Future Oncology | 7 | 6 | |
146 | 2013 | First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 16 | 16 | |
147 | 2013 | Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy | WEI-WU CHEN ; CHIA-CHI LIN ; TA-CHEN HUANG ; ANN-LII CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU | Anticancer Research | 11 | 11 | |
148 | 2012 | A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor | SHIH-HUNG YANG ; CHIA-CHI LIN ; ZHONG-ZHE LIN ; Tseng Y.-L.; RUEY-LONG HONG | Investigational New Drugs | 34 | 28 | |
149 | 2011 | Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients | Ng C.M.; Patnaik A.; Beeram M.; CHIA-CHI LIN ; Takimoto C.H. | Cancer Chemotherapy and Pharmacology | 24 | 10 | |
150 | 2011 | Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC | Medema R.H.; CHIA-CHI LIN ; CHIH-HSIN YANG | Clinical Cancer Research | 60 | 58 | |
151 | 2011 | Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma | Feng-Ming Hsu ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG | International Journal of Radiation Oncology Biology Physics | 38 | 36 | |
152 | 2011 | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery | JANG-MING LEE ; Yang S.-Y.; Yang P.-W.; CHIA-TUNG SHUN ; Wu M.-T.; CHIH-HUNG HSU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG ; Wang Y.-H.; Chuang T.-H.; JIN-SHING CHEN ; HSAO-HSUN HSU ; PEI-MING HUANG ; SHUENN-WEN KUO ; Lee Y.-C. | Annals of Surgical Oncology | 21 | 19 | |
153 | 2011 | RET mutations and medullary thyroid cancer | CHIA-CHI LIN | Journal of the Formosan Medical Association | 2 | 0 | |
154 | 2011 | PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma | Abou-Alfa G.K.; Chan S.L.; CHIA-CHI LIN ; Chiorean E.G.; Holcombe R.F.; Mulcahy M.F.; Carter W.D.; Patel K.; Wilson W.R.; Melink T.J.; Gutheil J.C.; Tsao C.-J. | Cancer Chemotherapy and Pharmacology | 26 | 25 | |
155 | 2011 | Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations | CHIA-CHI LIN ; CHIH-HSIN YANG | Drugs | 10 | 10 | |
156 | 2010 | Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors | CHIA-CHI LIN ; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; CHIH-HSIN YANG ; Mok T. | Journal of Thoracic Oncology | 26 | 22 | |
157 | 2010 | Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. | YU-YUN SHAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Discovery medicine | 13 | 12 | |
158 | 2010 | Cross-cultural adaptation and validation of the Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0): The development of the Taiwanese version | HUI-FEN MAO ; Chen, W.-Y.; Yao, G.; SHEAU-LING HUANG ; CHIA-CHI LIN ; KAI-PING GRACE YAO | Clinical Rehabilitation | 29 | 26 | |
159 | 2009 | Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer | CHIA-CHI LIN ; CHIH-HSIN YANG | Targeted Oncology | 11 | 9 | |
160 | 2009 | Phase i and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies | CHIA-CHI LIN ; Beeram M.; Rowinsky E.K.; Takimoto C.H.; Ng C.M.; Geyer Jr. C.E.; Denis L.J.; De Bono J.S.; Hao D.; Tolcher A.W.; Rha S.-Y.; Jolivet J.; Patnaik A. | Cancer Chemotherapy and Pharmacology | 2 | 2 | |
161 | 2009 | Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy | Feng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG | Annals of Surgical Oncology | 33 | 32 | |
162 | 2009 | Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFα-treated human aortic endothelial cells | Lin S.-J.; Hsieh F.-Y.; Chen Y.-H.; CHIA-CHI LIN ; Kuan I.-I.; SHU-HUEI WANG ; CHAU-CHUNG WU ; Chien H.-F.; Lin F.-Y.; YUH-LIEN CHEN | Histology and Histopathology | 20 | 20 | |
163 | 2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
164 | 2009 | Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Feng-Ming Hsu ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | International Journal of Radiation Oncology Biology Physics | 27 | 22 | |
165 | 2009 | Phase i study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors | CHIA-CHI LIN ; Calvo E.; Papadopoulos K.P.; Patnaik A.; Sarantopoulos J.; Mita A.C.; Preston G.G.; Mita M.M.; Rodon J.; Mays T.; Yeh I.-T.; O'Rourke P.; Takimoto C.H.; Dancey J.E.; Chen H.; Tolcher A.W. | Cancer Chemotherapy and Pharmacology | 15 | 13 | |
166 | 2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
167 | 2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |
168 | 2008 | Systemic therapy for metastatic urothelial carcinoma | CHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU ; Vogelzang N.J. | BJU International | 7 | 3 | |
169 | 2008 | Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study | FENG-MING HSU ; CHIA-CHI LIN ; JANG-MING LEE ; YIH-LEONG CHANG ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG | Journal of Surgical Oncology | 32 | 29 | |
170 | 2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
171 | 2008 | Down-regulated expression of RhoA in human conventional renal cell carcinoma | YEONG-SHIAU PU ; Wang C.-W.; Liu G.-Y.; Kuo Y.-Z.; CHAO YUAN HUANG ; Kang W.-Y.; CHIA-TUNG SHUN ; CHIA-CHI LIN ; Wu W.-J.; Hour T.-C. | Anticancer Research | 5 | 5 | |
172 | 2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
173 | 2007 | Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Vogelzang N.J.; YEONG-SHIAU PU | Journal of Urology | 20 | 18 | |
174 | 2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C. | Annals of Oncology | 39 | 36 | |
175 | 2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
176 | 2007 | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial | CHIA-CHI LIN ; CHIH-HUNG HSU ; Hour T.-C.; ANN-LII CHENG ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.; YEONG-SHIAU PU | Urologic Oncology: Seminars and Original Investigations | 6 | 6 | |
177 | 2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Anti-Cancer Drugs | 32 | 29 | |
178 | 2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 105 | 103 | |
179 | 2007 | Novel targeted therapies for advanced esophageal cancer | CHIA-CHI LIN ; Papadopoulos K.P. | Diseases of the Esophagus | 12 | 12 | |
180 | 2007 | Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Urology | 24 | 21 | |
181 | 2006 | Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study | CHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU | Anticancer Research | 0 | 0 | |
182 | 2006 | Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells | YEONG-SHIAU PU ; Hsieh M.-W.; Wang C.-W.; Liu G.-Y.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Guan J.-Y.; Lin S.-R.; Hour T.-C. | Biochemical Pharmacology | 38 | 35 | |
183 | 2006 | Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer | Hour T.-C.; YEONG-SHIAU PU ; CHIA-CHI LIN ; SHI-WEI HUANG ; Chen J.; Chiu A.W.; Chen C.-J.; CHAO-YUAN HUANG | Anticancer Research | 10 | 8 | |
184 | 2006 | Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU | Cancer | 24 | 24 | |
185 | 2004 | Changing trends of prostate cancer in Asia | YEONG-SHIAU PU ; Chiang H.-S.; CHIA-CHI LIN ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J. | Aging Male | 103 | 0 | |
186 | 2004 | Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide | Hour T.-C.; CHAO-YUAN HUANG ; CHIA-CHI LIN ; Chen J.; Guan J.-Y.; Lee J.-M.; YEONG-SHIAU PU | Anti-Cancer Drugs | 24 | 23 | |
187 | 2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
188 | 2002 | Comparison of bone marrow studies with blood culture for etiological diagnosis of disseminated mycobacterial and fungal infection in patients with acquired immunodeficiency syndrome | Ker C.-C.; CHIEN-CHING HUNG ; Huang S.-Y.; Chen M.-Y.; SZU-MIN HSIEH ; CHIA-CHI LIN ; SHAN-CHWEN CHANG ; KWEN-TAY LUH | Journal of Microbiology, Immunology and Infection | 30 | 0 | |
189 | 2001 | A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; Chen J.; Tsai T.-C.; ANN-LII CHENG ; YEONG-SHIAU PU | Anticancer Research | 14 | 13 | |
190 | 2001 | Genetic characterization of the rotaviruses associated with a nursery outbreak | Lee C.-N.; CHIA-CHI LIN ; CHUAN-LIANG KAO ; Zao C.-L.; Shih M.-C.; Chen H.-N. | Journal of Medical Virology | 29 |